Department of Orthopedic Surgery, School of Medicine, University of Occupational and Environmental Health, 1-1 Iseigaoka, Yahatanishi-Ku, Kitakyushu, 807-8555, Japan.
Department of Orthopedic Surgery, Ken-Ai Memorial Hospital, Fukuoka, 811-4313, Japan.
J Bone Miner Metab. 2023 Jul;41(4):557-566. doi: 10.1007/s00774-023-01430-1. Epub 2023 May 29.
The Seamless Treatment of Osteoporosis against Fractures (STOP-Fx) study was initiated to provide and continue therapeutic interventions for registered patients with osteoporotic fractures.
Women who visited six hospitals in the western Kitakyushu area for osteoporotic fractures between October 2016 and December 2018 were included in the study. Data collection for primary and secondary outcomes was conducted from October 2018 to December 2020, 2 years after STOP-Fx study enrollment. The primary outcome included the number of surgeries for osteoporotic fractures after the STOP-Fx study intervention, while secondary outcomes were the intervention rate of osteoporosis treatment, incidence and timing of secondary fractures, and factors associated with secondary fractures and loss to follow-up.
Concerning the primary outcome, the number of surgeries for osteoporotic fractures decreased since the STOP-Fx study initiation: 813 in 2017, 786 in 2018, 754 in 2019, 716 in 2020, and 683 in 2021. Regarding the secondary outcome, of the 805 patients enrolled, 445 were available for follow-up at 24 months. Of the 279 patients who were untreated for osteoporosis at enrollment, 255 (91%) were on treatment at 24 months. There were 28 secondary fractures, which were associated with increased tartrate-resistant acid phosphatase-5b and decreased lumbar spine bone mineral density during enrollment in the STOP-Fx study.
As the demographics and medical area served by six hospitals in the western Kitakyushu region have not changed significantly since the STOP-Fx study initiation, the STOP-Fx study may have contributed in decreasing the number of osteoporotic fractures.
骨质疏松性骨折无缝治疗（STOP-Fx）研究旨在为骨质疏松性骨折患者提供并持续治疗干预。
2016 年 10 月至 2018 年 12 月期间，在九州西部六个医院就诊的骨质疏松性骨折患者被纳入研究。主要和次要结局的数据收集于 2018 年 10 月至 2020 年 12 月进行，即 STOP-Fx 研究登记后 2 年。主要结局包括 STOP-Fx 研究干预后骨质疏松性骨折手术的数量，次要结局为骨质疏松症治疗的干预率、继发性骨折的发生率和时间以及与继发性骨折和失访相关的因素。
自 STOP-Fx 研究开始以来，骨质疏松性骨折手术的数量减少：2017 年 813 例，2018 年 786 例，2019 年 754 例，2020 年 716 例，2021 年 683 例。关于次要结局，在 805 名入组患者中，445 名在 24 个月时可进行随访。在入组时未接受骨质疏松症治疗的 279 名患者中，255 名（91%）在 24 个月时接受治疗。有 28 例继发性骨折，与 STOP-Fx 研究入组时耐酒石酸酸性磷酸酶-5b 增加和腰椎骨密度降低有关。
由于九州西部六个医院的人口统计学和医疗区域自 STOP-Fx 研究开始以来没有明显变化，STOP-Fx 研究可能有助于减少骨质疏松性骨折的数量。
